Closed calls
Basic page
Company Drugs Class Closing date Biothera Imprime PGG Innate Immune modulator 16 February 2015 Verastem VS-6063 Focal Adhesion Kinase (FAK) inhibitor 16 February 2015 MedImmune MEDI0639 Anti-DLL4 mAb 16 July 2014 MEDI3617 Anti-ANG2 mAb 16 July 2014 Astex AT13387 Non-ansamycin HSP90 inhibitor Second generation hypomethylating agent 30 May 2014 AZD1208...
Liverpool
Centre
The primary strategic areas of the Liverpool ECMC are pancreatic cancer and haemato-oncology, with expertise in cancer biology and pharmacology to develop novel biomarkers of efficacy, resistance and drug safety. Other areas of focus supported by local expertise are breast cancer with brain metastases, hepatobiliary cancers, head & neck cancers...
Potential new drug for metastatic urothelial bladder cancer (UBC)
Case Study
The results of a groundbreaking ECMC clinical trial lead by Professor Thomas Powles at the Barts Cancer Institute has major significance in finding new treatment for metastatic urothelial bladder cancer (UBC). The phase I trial was published in Nature and tested the effectiveness of the drug MPDL3280A (produced by Roche)...
The TRALA trial – targeted radiation
Case Study
A new technique developed by the Targeted Radiotherapy Group at the Southampton ECMC has outstanding implications for delivering very precise and focused treatment to malignancies in bone marrow. This would revolutionize radiation therapy for this type of cancer, as it would avoid irradiating healthy organs in compromised individuals. The AntiCd66...
National Lung Matrix Trial
Case Study
The National Lung Matrix Trial is the largest precision medicine trial in non-small cell lung cancer globally, and is pivotal in developing novel therapies for patients with this devastating disease. It is a clinician-led collaborative study between the University of Birmingham, Cancer Research UK, Astra Zeneca and Pfizer. The trial...
“Pick-a-winner” International Trial
Case Study
Acute Myeloid Leukaemia (AML), an aggressive cancer of myeloid cells in the blood, is commonly treated by intensive chemotherapy, which is not tolerated in all patients. As part of an exciting program aimed at improving outcomes of treatment in these patients, the LI-1 “Pick-a-winner” study evaluates new avenues for alternative...
Experimental Medicine in the UK
Basic page
In December 2011, the Life Sciences Strategy made a commitment to ensure that the UK becomes re-established as a global leader in the science sector. Alongside his promise came a ten-year Strategy for UK Life Sciences that has so far contributed £50 billion to our economy and has provided 165,000...
Success Stories
Basic page
Innovation and quality - trials in the Network The ECMC Network and the people within it are central to the delivery of innovative research . These are just a sample of trials and studies supported by the initiative that are demonstrating hallmarks of quality. First in class / First in...
Partnering Industry
Basic page
ECMC locations have forged multiple new links with industry during the year. 125 different companies conducted trials in the ECMC Network in 2013/14, not including partnerships that have been created around technologies and biomarkers. Highlights from ECMC-Industry partnerships: In Sheffield , colleagues from the departments of Chemistry, Dentistry and Oncology...
ComPAKT - fastest set-up to date
Case Study
ComPAKT (Combination Alliance study in partnership with AstraZeneca) is a good example of how the ECMC Network and Industry have combined their resources and expertise to address solid tumours. In fact this study set up has been the fastest to date within the ECMC Combinations Alliance , with the first...